| Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. | |
| | |
MedLine Citation:
|
PMID: 17868805 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We aimed to compare the effects of the angiotensin II receptor blocker (ARB) olmesartan versus the calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension. BACKGROUND: Angiotensin II receptor blockers are thought to have greater beneficial effects than CCBs on coronary vasomotion by directly blocking action of angiotensin II. METHODS: Twenty-six patients with untreated essential hypertension were prospectively assigned to treatment with either olmesartan (27.7 +/- 12.4 mg/day, n = 13) or amlodipine (5.6 +/- 1.5 mg/day, n = 13) for 12 weeks. Changes of corrected myocardial blood flow (DeltaMBF) and coronary vascular resistance (DeltaCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and superoxide dismutase (SOD) were also measured. RESULTS: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (-28.7 +/- 16.2 mm Hg vs. -26.7 +/- 10.8 mm Hg). In the olmesartan group, DeltaMBF tended to be greater (-0.15 +/- 0.19 ml/g/min vs. 0.03 +/- 0.17 ml/g/min, p = 0.09 by 2-way analysis of variance), and DeltaCVR was significantly decreased (7.9 +/- 23.5 mm Hg/[ml/g/min] vs. -16.6 +/- 18.0 mm Hg/[ml/g/min], p < 0.05) after treatment, whereas these parameters did not change in the amlodipine group (DeltaMBF: -0.15 +/- 0.12 ml/g/min vs. -0.12 +/- 0.20 ml/g/min; DeltaCVR: 6.5 +/- 18.2 mm Hg/[ml/g/min] vs. 4.8 +/- 23.4 mm Hg/[ml/g/min]). Serum SOD activity tended to increase (4.74 +/- 4.77 U/ml vs. 5.57 +/- 4.74 U/ml, p = 0.07 by 2-way analysis of variance) only in the olmesartan group. CONCLUSIONS: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independent of BP reduction. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs. |
| | |
Authors:
|
Masanao Naya; Takahiro Tsukamoto; Koichi Morita; Chietsugu Katoh; Tomoo Furumoto; Satoshi Fujii; Nagara Tamaki; Hiroyuki Tsutsui |
Related Documents
:
|
8283895 - The effect of reperfusion pressure on early outcomes after coronary artery bypass graft... 2346635 - Determination of clinical accuracy and nocturnal blood pressure pattern by new portable... 2397575 - Changes in cerebrovascular prostaglandins and thromboxane as a function of systemic blo... 1592455 - Influence of short-term blood pressure variability on blood pressure determinations. 3921675 - Nitroglycerin-controlled circulation in orthognathic surgery. 14565965 - Functional magnetic resonance signal changes in neural structures to baroreceptor refle... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2007-09-04 |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 50 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-09-17 Completed Date: 2007-10-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1144-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Amlodipine / administration & dosage* Blood Chemical Analysis Cohort Studies Coronary Circulation / drug effects* Coronary Stenosis / prevention & control Dose-Response Relationship, Drug Drug Administration Schedule Echocardiography Endothelium, Vascular / drug effects Female Follow-Up Studies Humans Hypertension / diagnosis, drug therapy* Imidazoles / administration & dosage* Male Middle Aged Positron-Emission Tomography Probability Prospective Studies Risk Assessment Tetrazoles / administration & dosage* Treatment Outcome Vasodilation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Imidazoles; 0/Tetrazoles; 0/olmesartan; 88150-42-9/Amlodipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report...
Next Document: Limitations of ejection fraction for prediction of sudden death risk in patients with coronary arter...